A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

BACKGROUND: Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade with ado-trastuzumab emtansine (T-DM1) and lapatinib plus nab-paclitaxel has show...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Tejal A., Ensor, Joe E., Creamer, Sarah L., Boone, Toniva, Rodriguez, Angel A., Niravath, Poly A., Darcourt, Jorge G., Meisel, Jane L., Li, Xiaoxian, Zhao, Jing, Kuhn, John G., Rosato, Roberto R., Qian, Wei, Belcheva, Anna, Schwartz, Mary R., Kaklamani, Virginia G., Chang, Jenny C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720931/
https://www.ncbi.nlm.nih.gov/pubmed/31477168
http://dx.doi.org/10.1186/s13058-019-1186-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720931/
https://www.ncbi.nlm.nih.gov/pubmed/31477168
http://dx.doi.org/10.1186/s13058-019-1186-0

Ejemplares similares